FDAapproval54% confidence
FDA grants traditional approval to selpercatinib for locally advanced or metastatic RET fusion-positive solid tumors
Source: FDA
Why This Matters
Why this matters: sets a approval precedent in the same sub-indication (her2) as Boehringer Ingelheim.
Regulatory Analysis
Supporting Context
- Therapeutic area
- Oncology · HER2 Alterations
- Sub-indication
- HER2
Related signal: Boehringer Ingelheim's Zongertinib Trial Targets Advanced Cancers with HER2 Alterations